Table 2.
Prior Treatment, Plasma Virus Levels, and CD4+ T Cell Levels of Animals
| Animal numbera | CD4+T cells/m3 | Plasma viral (RNA) copies/ml at start of ART treatment | ART/GC treatment |
|---|---|---|---|
| P455 | 808 | 51,529 | ± |
| P458 | 338 | 204,289 | ± |
| P459 | 767 | 9,583,762 | ± |
| P463 | 57 | 52,232 | ± |
| P469 | 507 | 33,508 | ± |
| P768 | 91 | 520,989 | ± |
| P792 | 66 | 1,259,330 | ± |
| P446 | 900 | 345,907 | +/+ |
| P453 | 900 | 587,252 | +/+ |
| P462 | 291 | 172,895 | +/+ |
| P465 | 269 | 82,226 | +/+ |
| P466 | 1,176 | 65,497 | +/+ |
| P775 | 335 | 701,216 | +/+ |
| P778 | 85 | 4,263,399 | +/+ |
| P789 | 336 | 59,004 | +/+ |
a
All the animals were part of a prior study (Shari Gordon et al., 2013, submitted) and became viremic following vaginal challenge and SIVmac251.
ART, antiretroviral therapy; GC, glucocorticoid.